WARREN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or...
WARREN, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or...
Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world...
WARREN, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or...
On track to submit Anaphylm™ (epinephrine) Sublingual Film NDA in Q1 2025Actively recruiting subjects in the...
WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or...
Reaffirms New Drug Application (NDA) first quarter 2025 submission guidanceConfirms no additional adult...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads